Author:
Mukherjee Biswajit,Dutta Debasmita,Ghosh Prasanta,Paul Brahamacharry,Sen Ramkrishna,Chakraborty Samrat
Reference124 articles.
1. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR (2016) Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res 33(10):2373–2387
2. Manzo L (2014) Nanotoxicology and safety evaluation of Nanomedicines. In: Proceedings of the 14th IEEE international conference on nanotechnology, Toronto, Canada, august 18–21
3. Ventola CL (2012) The nanomedicine revolution: part 1: emerging concepts. P & T. 37(9):512–525
4. Havel HA, Finch G, Strode P, Wolfgang M, Zale S, Bobe I, Youssoufian H, Peterson M, Liu M (2016) Nanomedicines: from bench to bedside and beyond. AAPS J 18(6):1373–1378
5. Hu X, Miller L, Richman S, Hitchman S, Glick G, Liu S, Zhu Y, Crossman M, Nestorov I, Gronke RS, Baker DP, Rogge M, Subramanyam M, Davar G (2012) A novel PEGylated interferon beta1a for multiple sclerosis: safety, pharmacology, and biology. J Clin Pharmacol 52(6):798–808